Solid Biosciences Inc.

Solid Biosciences Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Solid Biosciences Inc. is not a good value stock. Solid Biosciences Inc. is not very popular among insiders. Solid Biosciences Inc. is a mediocre stock to choose.
Log in to see more information.
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular...
SLDB Fundamental Data by TradingView

News

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Globe Newswire CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the Company ), a life sciences company developing precision genetic medicines for neuromuscular and...\n more…

Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences to Participate at Upcoming Investor Conferences

Globe Newswire CHARLESTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the Company or Solid ), a life sciences company developing precision genetic medicines for...\n more…

Head-To-Head Contrast: Solid Biosciences (NASDAQ:SLDB) versus Senti Biosciences (NASDAQ:SNTI)
Head-To-Head Contrast: Solid Biosciences (NASDAQ:SLDB) versus Senti Biosciences (NASDAQ:SNTI)

Zolmax Senti Biosciences (NASDAQ:SNTI - Get Free Report) and Solid Biosciences (NASDAQ:SLDB - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two...\n more…

FY2024 Earnings Estimate for Solid Biosciences Inc. (NASDAQ:SLDB) Issued By Cantor Fitzgerald
FY2024 Earnings Estimate for Solid Biosciences Inc. (NASDAQ:SLDB) Issued By Cantor Fitzgerald

Ticker Report Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2024 earnings per share estimates for shares of Solid Biosciences in a report issued on...\n more…

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Rating of "Buy" from Analysts
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Average Rating of "Buy" from Analysts

Ticker Report Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) has been given an average recommendation of "Buy" by the nine brokerages that are currently covering the stock, Marketbeat.com reports. Eight...\n more…

Chardan Capital Weighs in on Solid Biosciences Inc.'s FY2024 Earnings (NASDAQ:SLDB)
Chardan Capital Weighs in on Solid Biosciences Inc.'s FY2024 Earnings (NASDAQ:SLDB)

Ticker Report Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at Chardan Capital issued their FY2024 EPS estimates for Solid Biosciences in a research note issued on Monday, August...\n more…